Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka

被引:1
作者
Gunasekara, Agampodi Danushi Mendis [1 ,2 ]
Youngkong, Sitaporn [1 ,3 ]
Anothaisintawee, Thunyarat [1 ,4 ]
Dejthevaporn, Thitiya [5 ]
Fernandopulle, Rohini [2 ]
Chaikledkaew, Usa [1 ,3 ]
机构
[1] Mahidol Univ, Hlth Technol Assessment MUHTA Grad Program, Bangkok, Thailand
[2] Gen Sir John Kotelawala Def Univ, Fac Med, Dept Paraclin Sci, Ratmalana, Sri Lanka
[3] Mahidol Univ, Fac Pharm, Dept Pharm, Social & Adm Pharm Div, 447 Sri Ayudhaya Rd, Bangkok, Thailand
[4] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Family Med, Bangkok, Thailand
[5] Mahidol Univ, Ramathibodi Hosp, Div Med Oncol, Bangkok, Thailand
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
基金
比尔及梅琳达.盖茨基金会;
关键词
Cost-utility analysis; Neoadjuvant; HER2 positive breast cancer; Targeted therapy; PHASE-II TRIAL; OPEN-LABEL; ECONOMIC-EVALUATION; SURVIVAL OUTCOMES; TRASTUZUMAB; PERTUZUMAB; MULTICENTER; LAPATINIB; NEOALTTO; CHEMOTHERAPY;
D O I
10.1038/s41598-024-67598-2
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This study aimed to assess the cost-utility and budget impact of dual to single HER2 targeted neoadjuvant therapy for HER2-positive breast cancer in Sri Lanka. A five-health state Markov model with lifetime horizon was used to assess the cost-utility of neoadjuvant trastuzumab (T) plus pertuzumab (P) or lapatinib (L) compared to single therapy of T with chemotherapy (C), in public healthcare system and societal perspectives. Input parameters were estimated using local data, network meta-analysis, published reports and literature. Costs were adjusted to year 2021 (1USD = LKR194.78). Five-year budget impact for public healthcare system was assessed. Incremental cost-effectiveness ratios in societal perspective for neoadjuvantLTC plus adjuvantT (strategy 3), neoadjuvantPTC plus adjuvantT (strategy 2), neoadjuvantLTC plus adjuvantLT (strategy 5), and neoadjuvantPTC plus adjuvantPT (strategy 4) compared to neoadjuvantTC plus adjuvantT (strategy 1) were USD2716, USD5600, USD6878, and USD12127 per QALY gained, respectively. One GDP per-capita (USD3815) was considered as the cost-effectiveness threshold for the analysis. Even though only the ICER for strategy 3 was cost-effective, uncertainty of efficacy parameter was revealed. For strategy 2 neoadjuvant PTC plus adjuvant T, a 25% reduction of neoadjuvant regimen cost was required to be cost effective for use in early HER2 positive breast cancer.
引用
收藏
页数:13
相关论文
共 64 条
  • [1] [Anonymous], 2021, National Guidelines for the Management of Early and Locally Advanced Breast Cancer in Sri Lanka
  • [2] [Anonymous], 2020, Economic and Social Statistics of Sri Lanka
  • [3] [Anonymous], 2022, Buying and Selling Exchange Rates
  • [4] [Anonymous], 2021, BREAST CANC
  • [5] [Anonymous], 2020, Pathology Based Cancer Frequency Data - Sri Lanka: 2017
  • [6] [Anonymous], 2021, Financial Details: Cost Accounting
  • [7] [Anonymous], 2022, Inflation in December 2022
  • [8] [Anonymous], 2016, Committee Papers
  • [9] [Anonymous], 2023, Inflation and prices-Monthly NCPI
  • [10] [Anonymous], 2021, Palliative Care Manual for Health Care Professionals in Sri Lanka, V2